Please ensure Javascript is enabled for purposes of website accessibility

Inovio Wins $71 Million Department of Defense Contract for Its COVID-19 Vaccine Delivery Devices

By Keith Speights – Jun 23, 2020 at 10:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech also said it will announce results from phase 1 testing of its COVID-19 vaccine candidate, INO-4800, by the end of June.

Inovio Pharmaceuticals (INO 2.68%) announced on Tuesday that it has been awarded a $71 million Defense Department contract to assist it in ramping up production of its Cellectra 3PSP smart devices, and to purchase a quantity of its Cellectra 2000 devices. Both devices are used to deliver Inovio's experimental COVID-19 vaccine, INO-4800, into the skin.

The Cellectra 3PSP could be especially well-suited for the Defense Department's needs. It's a durable hand-held device that administers INO-4800 using an electrical field -- a method that allows the vaccine  to more easily and efficiently enter the patient's cells. The devices can be stockpiled without requiring maintenance. And INO-4800 could also be a good fit for the military, as it's the only nucleic-acid-based COVID-19 vaccine that doesn't have to be frozen for storage or transportation.

Gloved hands holding coronavirus vaccine bottles

Image source: Getty Images.

The contract was initiated by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies, which takes the lead on providing medical solutions for the U.S. military during a crisis. In 2019, Inovio received $8.1 million in funding from the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium to develop the Cellectra 3PSP device. The company also received separate $5 million grants to test its Cellectra 3PSP device from the Bill and Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations.

Inovio began phase 1 clinical testing of INO-4800 in April. It expects to report interim results from those studies by the end of June, and to begin phase 2/3 testing in July or August. CEO J. Joseph Kim said that the Defense Department contract announced on Tuesday "further supports Inovio's large-scale production of devices and arrays to deliver potentially hundreds of millions of doses of INO-4800 next year to combat the global COVID-19 pandemic."

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.73 (2.68%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.